This study evaluate either Toripalimab or combined with chemotherapy as neoadjuvant treatment for patients with head and neck squamous cell carcinoma. Participants in arm A receive Toripalimab, in arm B receive Toripalimab plus PC (paclitaxel and carboplatin), arm C with Toripalimab plus modified TPF(paclitaxel and cisplatin and 5-fu).

Inclusion Criteria:

• Confirmed pathologic or cytologic diagnosis of squamous cell carcinoma of head and neck;
• Resectable or potentially resectable lesion;
• ECOG PS 0-1;
• Age >18 years old;
• At least one target lesion according to RECIST 1.1;
• Proper function of the cardiovascular system, liver, kidney and bone marrow for receiving chemotherapy and surgery;

Exclusion Criteria:

• Distant metastasis;
• Second malignancy within 5 years;
• Nasopharyngeal carcinoma;
• Active autoimmune diseases;
• HIV infected;
• Required prednisone dose >=10mg daily;
• Heart attack within 6 months;
• Stroke within 6 months;
• Other conditions that investigators consider the patients are not suitable for PD-1antibody;